The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
Table 1
Differences between asthma and COPD presentation, etiology, and pathophysiology [2, 3].
Asthma
COPD
Characteristic symptom
Variable (i.e., wheezing, shortness of breath, chest tightness, or cough may be the prominent symptom, depending on the patient)
Chronic and progressive dyspnea, particularly during exertion
Other symptoms
Wheeze, shortness of breath, chest tightness, and cough
Cough, sputum production, wheezing, and chest tightness In severe cases: fatigue, weight loss, exercise intolerance, and anorexia
Pathophysiology
Airway narrowing caused by hyperresponsiveness, inflammation, structural remodeling, and environmental exposures
Airway narrowing caused by chronic inflammation as a response to cigarette smoke or noxious environmental stimuli, parenchymal tissue destruction, and small airway fibrosis; high prevalence of comorbidities
